FR2437834A1 - Compositions pharmaceutiques a base de l-serine ou de glycine - Google Patents

Compositions pharmaceutiques a base de l-serine ou de glycine

Info

Publication number
FR2437834A1
FR2437834A1 FR7828353A FR7828353A FR2437834A1 FR 2437834 A1 FR2437834 A1 FR 2437834A1 FR 7828353 A FR7828353 A FR 7828353A FR 7828353 A FR7828353 A FR 7828353A FR 2437834 A1 FR2437834 A1 FR 2437834A1
Authority
FR
France
Prior art keywords
serine
glycine
mongolism
debility
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7828353A
Other languages
English (en)
Other versions
FR2437834B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR7828353A priority Critical patent/FR2437834A1/fr
Publication of FR2437834A1 publication Critical patent/FR2437834A1/fr
Application granted granted Critical
Publication of FR2437834B1 publication Critical patent/FR2437834B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MEDICAMENTS ET COMPOSITIONS PHARMACEUTIQUES ADMINISTRABLES PAR LA VOIE ORALE, DONT LA SUBSTANCE ACTIVE EST LA L-SERINE OU LA GLYCINE. CES MEDICAMENTS ET COMPOSITIONS CONVIENNENT AU TRAITEMENT DES DEFICITS DU FONCTIONNEMENT CEREBRAL TELS QUE LA TRISOMIE 21 (MONGOLISME) OU LA MALADIE D'ALZHEIMER, ET PLUS GENERALEMENT, LA DEBILITE MENTALE.
FR7828353A 1978-10-04 1978-10-04 Compositions pharmaceutiques a base de l-serine ou de glycine Granted FR2437834A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7828353A FR2437834A1 (fr) 1978-10-04 1978-10-04 Compositions pharmaceutiques a base de l-serine ou de glycine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7828353A FR2437834A1 (fr) 1978-10-04 1978-10-04 Compositions pharmaceutiques a base de l-serine ou de glycine

Publications (2)

Publication Number Publication Date
FR2437834A1 true FR2437834A1 (fr) 1980-04-30
FR2437834B1 FR2437834B1 (fr) 1981-04-10

Family

ID=9213331

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7828353A Granted FR2437834A1 (fr) 1978-10-04 1978-10-04 Compositions pharmaceutiques a base de l-serine ou de glycine

Country Status (1)

Country Link
FR (1) FR2437834A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124091A2 (fr) * 1983-04-29 1984-11-07 Merrell Dow Pharmaceuticals Inc. Traitement des attaques brusques et compositions pharmaceutiques utiles au traitement
WO1988009171A1 (fr) * 1987-05-19 1988-12-01 Baylor College Of Medicine Phosphoethanolamine permettant le traitement de la maladie d'alzheimer
EP0481294A1 (fr) * 1990-10-19 1992-04-22 Spirig Ag Pharmazeutische Präparate Préparation pharmaceutique solide à dissolution rapide contenant de la S-(carboxyméthyl)-L-cystéine et/ou de la N-acétylcystéine
WO1993013764A1 (fr) * 1992-01-10 1993-07-22 Irina Alexeevna Komissarova Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
WO1994000132A1 (fr) * 1992-06-24 1994-01-06 Pierre Fabre Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux
EP0774252A1 (fr) * 1994-05-06 1997-05-21 Kanebo Ltd. Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite
EP1004301A1 (fr) * 1997-07-28 2000-05-31 The Institute Of Physical & Chemical Research Agent promoteur de protection et de survie des cellules du systeme nerveux central
EP1060750A2 (fr) * 1993-03-29 2000-12-20 Queen's University at Kingston Procédé de traitement de l'amyloidose
JP2007504197A (ja) * 2003-09-04 2007-03-01 ビオグルト ビオガルデ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト ホスファチジルセリン塩基の生理学的活性組成物
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7754761B2 (en) 1993-03-29 2010-07-13 Bellus Health (International) Limited Sulfonated compounds and compositions for treating amyloidosis
US8178580B2 (en) 2005-04-15 2012-05-15 Kiacta Sarl Formulations and methods for treating amyloidosis
US8642801B2 (en) 2003-06-23 2014-02-04 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
WO2016116582A1 (fr) * 2015-01-23 2016-07-28 Nestec S.A. Traitement ou prévention de l'inflammation à l'aide de sérine
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US3873722A (en) * 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US3873722A (en) * 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124091A3 (en) * 1983-04-29 1987-10-07 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
EP0124091A2 (fr) * 1983-04-29 1984-11-07 Merrell Dow Pharmaceuticals Inc. Traitement des attaques brusques et compositions pharmaceutiques utiles au traitement
WO1988009171A1 (fr) * 1987-05-19 1988-12-01 Baylor College Of Medicine Phosphoethanolamine permettant le traitement de la maladie d'alzheimer
EP0481294A1 (fr) * 1990-10-19 1992-04-22 Spirig Ag Pharmazeutische Präparate Préparation pharmaceutique solide à dissolution rapide contenant de la S-(carboxyméthyl)-L-cystéine et/ou de la N-acétylcystéine
US5643954A (en) * 1992-01-10 1997-07-01 Komissarova; Irina Alexeevna Method of preventing and alleviating stress in a healthy mammal in need thereof
WO1993013764A1 (fr) * 1992-01-10 1993-07-22 Irina Alexeevna Komissarova Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
WO1994000132A1 (fr) * 1992-06-24 1994-01-06 Pierre Fabre Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux
EP1060750A2 (fr) * 1993-03-29 2000-12-20 Queen's University at Kingston Procédé de traitement de l'amyloidose
EP1060750A3 (fr) * 1993-03-29 2003-03-26 Queen's University at Kingston Procédé de traitement de l'amyloidose
US7754761B2 (en) 1993-03-29 2010-07-13 Bellus Health (International) Limited Sulfonated compounds and compositions for treating amyloidosis
EP0774252A4 (fr) * 1994-05-06 2000-04-26 Kanebo Ltd Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite
EP0774252A1 (fr) * 1994-05-06 1997-05-21 Kanebo Ltd. Potentialisateur de cytokine et remede pour des maladies dans lesquelles l'activite de la cytokine est reduite
EP1004301A1 (fr) * 1997-07-28 2000-05-31 The Institute Of Physical & Chemical Research Agent promoteur de protection et de survie des cellules du systeme nerveux central
EP1004301A4 (fr) * 1997-07-28 2002-11-13 Riken Agent promoteur de protection et de survie des cellules du systeme nerveux central
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US8642801B2 (en) 2003-06-23 2014-02-04 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
JP2007504197A (ja) * 2003-09-04 2007-03-01 ビオグルト ビオガルデ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト ホスファチジルセリン塩基の生理学的活性組成物
US8178580B2 (en) 2005-04-15 2012-05-15 Kiacta Sarl Formulations and methods for treating amyloidosis
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10238611B2 (en) 2006-10-12 2019-03-26 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US10857109B2 (en) 2006-10-12 2020-12-08 Bellus Health, Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2016116582A1 (fr) * 2015-01-23 2016-07-28 Nestec S.A. Traitement ou prévention de l'inflammation à l'aide de sérine

Also Published As

Publication number Publication date
FR2437834B1 (fr) 1981-04-10

Similar Documents

Publication Publication Date Title
FR2437834A1 (fr) Compositions pharmaceutiques a base de l-serine ou de glycine
AU6060896A (en) Oral 1alpha-hydroxyprevitamin D
UA37244C2 (uk) Спосіб лікування або профілактики клінічних розладів, виліковних прогестероном, у пацієнтів жіночої статі
EP0552256A4 (fr)
DE3669103D1 (de) Ibuprofen enthaltendes arzneimittel.
YU49083B (sh) Postupak za dobijanje farmaceutske kompozicije koja sadrži budesonid i formoterol
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
CA2075904A1 (fr) Methode de traitement du syndrome pre-menstruel
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
AU552547B2 (en) Nonapeptide for treatment of drug withdrawal symptoms
TW360537B (en) Fatty acid derivatives
ZA885944B (en) Transdermal therapeutic system
FI851686A0 (fi) Redskap foer anvaendning vid behandling av osteoporosis.
EP0302714A3 (fr) Composition pharmaceutique pour le traitement des maladies affaiblissant les os
HUT59600A (en) Process for producing pharmaceutical compositions containing 5-methyl-isoxazoe-4-carboxylik-anilides or alpha-/2-hydroxy-ethylidene/-alpha-cyano-acetic-anilides for treating eye-diseases
AU574978B2 (en) Method for treatment of antidiuresis employing serine derivatives
EP0345247A3 (fr) Utilisation de derivés organiques monosubstitués du selenium pour la préparation d'un médicament, le médicament et sa préparation
EP0035597A3 (en) Pharmaceutical preparations
DE3687865D1 (de) Verwendung von probucol zur herstellung eines arzneimittels fuer die behandlung von herzarrhythmie.
FR2308372A2 (fr) Produits pharmaceutiques contenant un compose organosilicie en tant qu'agent actif
FR2389377A1 (en) Antiinflammatory, antirheumatic medicament - comprises 1 alpha-hydroxy-cholecalciferol
IT1224250B (it) Associzione del depiprazolo con la morfina
EP0207882A3 (fr) Utilisation de la terguride pour la fabrication d'un médicament pour le traitement de maladies gériatriques
Turpin et al. An attempt of prevention and treatment of hoof-rot and sole ulcer by oral administration of zinc joined to specific vaccination.
USD225467S (en) Medical equipment tray

Legal Events

Date Code Title Description
ST Notification of lapse
ST Notification of lapse